Supercharged cord blood cells take on resistant blood cancers

NCT ID NCT07444632

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recognize and attack cancer cells while resisting the tumor's attempts to shut them down. Up to 60 participants will receive these cells along with chemotherapy to prepare the body. The main goal is to check safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered natural killer (NK) cells from cord blood, modified to target cancer cells and resist tumor suppression
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat lymphoid cancers who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, focused on safety. The approach is experimental, may not work, and could cause serious side effects like immune reactions or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma Hodgkins lymphoma lymphoid system disorder T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA LYMPHOID

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.